Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $30.00 price target on the stock.
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion [Yahoo! Finance]
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution [Yahoo! Finance]
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution